Hikma Pharmaceuticals PLC
HKMPYOTCHealthcare● Active
$39.08
$-0.19(-0.47%)
Market Cap$4.3B
P/E Ratio—
52W High$56.91
52W Low$31.8
Hikma Pharmaceuticals PLC (HKMPY) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · HKMPY · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $3.36B | $3.13B | $2.88B | $2.52B | $2.55B |
| Cost of Revenue | $2.01B | $1.71B | $1.47B | $1.28B | $1.25B |
| Gross Profit | $1.34B | $1.42B | $1.41B | $1.24B | $1.30B |
| Gross Margin %(computed) | 40.04% | 45.25% | 48.94% | 49.19% | 50.96% |
| Operating Expenses | |||||
| R&D Expenses | $0.15B | $0.14B | $0.15B | $0.14B | $0.14B |
| G&A Expenses | $0.00B | $0.57B | $0.64B | $0.51B | $0.49B |
| Total Operating Expenses | $0.72B | $0.80B | $1.04B | $0.96B | $0.72B |
| Operating Income | $0.63B | $0.61B | $0.37B | $0.28B | $0.58B |
| Operating Margin %(computed) | 18.63% | 19.57% | 12.77% | 11.20% | 22.80% |
| Interest Income | $0.01B | $0.01B | $0.01B | $0.00B | $0.03B |
| Interest Expense | $0.11B | $0.09B | $0.09B | $0.07B | $0.07B |
| Income Before Tax | $0.52B | $0.45B | $0.28B | $0.23B | $0.54B |
| Income Tax Expense | $0.11B | $0.09B | $0.09B | $0.04B | $0.12B |
| Net Income | $0.40B | $0.36B | $0.19B | $0.19B | $0.42B |
| Net Margin %(computed) | 12.00% | 11.48% | 6.61% | 7.47% | 16.49% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $3.66 | $3.24 | $1.70 | $1.68 | $3.64 |
| Wtd Avg Shares | 0.11B | 0.11B | 0.11B | 0.11B | 0.12B |
| EBITDA | $0.84B | $0.73B | $0.56B | $0.69B | $0.77B |
| EBITDA Margin %(computed) | 24.96% | 23.25% | 19.44% | 27.33% | 30.00% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Hikma Pharmaceuticals PLC data
About Hikma Pharmaceuticals PLC (HKMPY) Income Statement
Hikma Pharmaceuticals PLC (HKMPY) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, HKMPY reported revenue of $3.36B, gross profit of $1.34B (gross margin 40.04%), and net income of $0.40B — a net profit margin of 12.00%.
Frequently asked questions
HKMPY · 4 questionsHikma Pharmaceuticals PLC (HKMPY) reported revenue of $3.36B for 2025, up 7.3% year-over-year.
HKMPY revenueHKMPY salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09